Clesrovimab-cfor
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anum Ijaz M.B.B.S., M.D.[2]
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Clesrovimab-cfor is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor that is FDA approved for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.. Common adverse reactions include injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%)..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
FDA-labeled Indications
- ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
Recommended Dosage
- The recommended dose for neonates and infants born during or entering their first RSV season is 105 mg administered as a single intramuscular (IM) injection.
- For neonates and infants born during the RSV season, administer ENFLONSIA once starting from birth.
- For infants born outside the RSV season, administer ENFLONSIA once prior to the start of their first RSV season considering the duration of protection provided by ENFLONSIA.
Infants Undergoing Cardiac Surgery with Cardiopulmonary Bypass
- For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose administered as an IM injection is recommended as soon as the infant is stable after surgery to ensure adequate clesrovimab-cfor serum levels.
Dosage Forms and Strengths
- Injection: 105 mg/0.7 mL clear to slightly opalescent, colorless to slightly yellow solution in a single-dose prefilled syringe.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Clesrovimab-cfor in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Clesrovimab-cfor in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Clesrovimab-cfor FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Clesrovimab-cfor in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Clesrovimab-cfor in pediatric patients.
Contraindications
ENFLONSIA is contraindicated in infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA.
Warnings
Hypersensitivity Including Anaphylaxis
- Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies.
- If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
RSV Diagnostic Test Interference
- Clesrovimab-cfor may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies.
- Confirmation using a reverse transcriptase polymerase chain reaction (RT-PCR) assay is recommended when rapid antigen assay results are negative and clinical observations are consistent with RSV infection
Adverse Reactions
Clinical Trials Experience
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- The safety of ENFLONSIA was evaluated in 2,858 infants who received ENFLONSIA in Phase 2b/3 and Phase 3 clinical trials (Trial 004 and Trial 007).
Neonates and Infants Entering Their First RSV Season (Trial 004)
- Trial 004 was a Phase 2b/3, randomized, double-blind placebo-controlled, multisite trial conducted in early and moderate preterm infants (≥29 to <35 weeks gestational age (GA)) and late preterm and full-term infants (≥35 weeks GA).
- Participants were randomized 2:1 and received a single 105 mg dose of ENFLONSIA (N=2,412, including 422 early and moderate preterm infants) or saline placebo (N=1,202, including 209 early and moderate preterm infants) by IM injection. Participants were monitored for 30 minutes post-dose.
- Safety was assessed using an electronic diary device from Days 1 through 42 post-dose. Participants were monitored for serious adverse events (SAEs) through the duration of their participation for up to 365 days post-dose.
- A subset of participants was monitored for SAEs for up to 515 days post-dose.
Infants Born at ≤35 Weeks Gestational Age and Infants with Chronic Lung Disease (CLD) of Prematurity or Hemodynamically Significant Congenital Heart Disease (CHD) Entering Their First RSV Season (Trial 007)
- Trial 007 was a Phase 3, randomized, partially-blind, palivizumab-controlled, multisite trial conducted in infants at increased risk of severe RSV disease.
- Participants were randomized and received a single 105 mg dose of ENFLONSIA (N=446) followed by a dose of placebo one month later or 3 to 5 monthly doses of 15 mg/kg palivizumab (N=450) by IM injection.
- Of the 446 participants who received ENFLONSIA, 176 had CLD of prematurity or CHD and 270 were early or moderate preterm infants (≤35 weeks GA) without CLD of prematurity or CHD. Participants were monitored for 30 minutes post-dose. Safety was assessed using an electronic diary device from Day 1 (dose 1) through 14 days post-dose 2, and 14 days after each subsequent dose. Participants were monitored for serious adverse events in the first RSV season for up to 365 days.
- The safety profile of ENFLONSIA in infants at increased risk of severe RSV disease entering their first season was similar to palivizumab and consistent with the safety profile of ENFLONSIA in infants in Trial 004.
Postmarketing Experience
There is limited information regarding Clesrovimab-cfor Postmarketing Experience in the drug label.
Drug Interactions
Interference with Rapid Antigen Detection RSV Diagnostic Assays
- Clesrovimab-cfor may interfere with some immunologically-based RSV diagnostic assays (i.e., rapid antigen tests) as observed in laboratory studies.
- Confirmation using an RT-PCR assay is recommended when rapid antigen RSV diagnostic assay results are negative and clinical observations are consistent with RSV infection.
- Clesrovimab-cfor does not interfere with RT-PCR diagnostic assays.
Use in Specific Populations
Pregnancy
- ENFLONSIA is not indicated for use in females of reproductive potential.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Clesrovimab-cfor in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Clesrovimab-cfor during labor and delivery.
Nursing Mothers
- ENFLONSIA is not indicated for use in females of reproductive potential.
Pediatric Use
- The safety and effectiveness of ENFLONSIA have been established for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and the information on this use is discussed throughout the labeling.
- The safety and effectiveness of ENFLONSIA have not been established in children older than 12 months of age.
Geriatic Use
There is no FDA guidance on the use of Clesrovimab-cfor in geriatric settings.
Gender
There is no FDA guidance on the use of Clesrovimab-cfor with respect to specific gender populations.
Race
There is no FDA guidance on the use of Clesrovimab-cfor with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Clesrovimab-cfor in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Clesrovimab-cfor in patients with hepatic impairment.
Females of Reproductive Potential and Males
- ENFLONSIA is not indicated for use in females of reproductive potential.
Immunocompromised Patients
There is no FDA guidance one the use of Clesrovimab-cfor in patients who are immunocompromised.
Administration and Monitoring
Administration
ENFLONSIA must be administered by a healthcare provider.
Add syringe image
- Before injection, remove ENFLONSIA from the refrigerator and allow the prefilled syringe to come to room temperature for approximately 15 minutes.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- ENFLONSIA is a clear to slightly opalescent, colorless to slightly yellow solution. This product should not be used if particulate matter or discoloration is found.
- Do not use if the prefilled syringe has been dropped or damaged, the security seal on the carton has been broken, or the expiration date has passed.
- Step 1: Hold the syringe barrel in one hand and unscrew the tip cap by twisting it counter-clockwise with the other hand. Do not remove the Luer Lock adaptor and the finger flange extender.
- Step 2: Attach a sterile Luer Lock needle by twisting in a clockwise direction until the needle fits securely on the syringe. Due to the viscosity of the product, use a 22- to 25-gauge needle.
- Step 3: Inject the entire contents of the ENFLONSIA prefilled syringe intramuscularly in the anterolateral aspect of the thigh. ENFLONSIA should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
- Step 4: Discard syringe into a sharps container.
Co-administration with Childhood Vaccines and Immunoglobulin Products
- ENFLONSIA can be given concomitantly with childhood vaccines.
- When ENFLONSIA is administered concomitantly with injectable vaccines, it should be given using a separate syringe and at a different injection site.
- Do not mix ENFLONSIA with any vaccines or medications in the same syringe or vial.
- There is no information regarding co-administration of ENFLONSIA with other immunoglobulin products.
- There are no data regarding substitution of ENFLONSIA for palivizumab once prophylaxis treatment is initiated with palivizumab for the RSV season.
Monitoring
There is limited information regarding Clesrovimab-cfor Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Clesrovimab-cfor and IV administrations.
Overdosage
- There is limited experience of overdose with ENFLONSIA.
- There is no specific treatment for an overdose with ENFLONSIA.
- In the event of an overdose, the infant should be monitored for the occurrence of adverse reactions and provided with symptomatic treatment as appropriate.
Pharmacology
There is limited information regarding Clesrovimab-cfor Pharmacology in the drug label.
Mechanism of Action
ENFLONSIA is a monoclonal antibody with anti-RSV activity.
Microbiology
- Clesrovimab-cfor is a recombinant human immunoglobulin G1 kappa (IgG1κ) neutralizing monoclonal antibody with a YTE triple amino acid substitution (M252Y/S254T/T256E) in the Fc region which increases binding to the neonatal Fc receptor leading to an extended serum half-life.
- Passive immunity is provided by clesrovimab-cfor, which targets the extracellular domain of the RSV fusion (F) protein to prevent fusion of the viral and cellular membranes and viral entry.
- Clesrovimab-cfor binds to a conserved epitope on antigenic site IV on the F protein and binds to RSV A pre-fusion F glycoprotein and post-fusion F glycoprotein with equilibrium dissociation constant values (KD) of 71 pM and 480 pM, respectively.
Structure
Clesrovimab-cfor is a respiratory syncytial virus F protein-directed fusion inhibitor. Clesrovimab-cfor is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced in recombinant Chinese hamster ovary (CHO) cells. The molecular weight is approximately 149 kDa.
Pharmacodynamics
- RSV serum neutralizing antibody titer correlates with clesrovimab-cfor serum concentration.
- Following IM administration of clesrovimab-cfor in infants, the RSV neutralizing antibody titers in serum were estimated to be approximately 7 times higher than baseline at 4 hours after clesrovimab-cfor dosing and maximum titers were reached by day 7, for a typical infant weighing 5 kg.
Exposure-Response Relationship In the Phase 2b/3 trial evaluating the recommended dose of clesrovimab-cfor (a single dose of 105 mg) in healthy preterm and full-term infants (Trial 004), no significant relationship was observed between AUC (from day 1 to day 150) and clinical outcomes (e.g., RSV-associated Medically Attended Lower Respiratory Infection (MALRI)).
Duration of Protection Based on clinical trial data, the duration of protection demonstrated by a single dose of ENFLONSIA extends through 5 months.
Pharmacokinetics
- The PK of clesrovimab-cfor is approximately dose-proportional following a single IM administration of doses ranging from 20 mg to 210 mg in infants.
- Following IM administration of the 105 mg recommended dose, the geometric mean (% geometric CV) area under the time concentration curve from day 1 to day 150 (AUC0-150) is 6,470 mcg×d/mL (22.6%), peak concentration (Cmax) is 120 mcg/mL (25.4%), and the concentration at day 150 (C150) is 10.3 mcg/mL (36.6%).
- In the first RSV season, the clesrovimab-cfor serum exposures were similar in neonates and infants in Trial 004, in preterm neonates and infants born at less than or equal to 35 weeks GA (including less than 29 weeks GA) in Trial 007, and in neonates and infants with CLD or CHD in Trial 007.
- Absorption
The median time to maximum concentration is 6.5 days (5.9, 7.4 which are the 2.5 and 97.5 percentiles, respectively).
- Distribution
The estimated apparent volume of distribution for clesrovimab-cfor is 830 mL, for a typical infant weighing 5 kg.
- Elimination
The clesrovimab-cfor terminal half-life is approximately 44.0 days and the estimated apparent clearance is 19.7 mL/day for a typical infant weighing 5 kg.
- Metabolism
Clesrovimab-cfor is degraded into small peptides by catabolic pathways.
- Specific Populations
No clinically significant differences in the pharmacokinetics of clesrovimab-cfor were observed based on race or vulnerability to severe RSV disease (i.e., CLD, CHD, or GA <29 weeks). An effect of renal or hepatic impairment on clesrovimab-cfor pharmacokinetics is not expected.
- Drug Interaction Studies
Since clesrovimab-cfor is eliminated by catabolism, no metabolic drug-drug interactions are expected. However, no formal drug interaction studies have been performed with ENFLONSIA.
- Clinical Studies
Vaccines: In clinical trials, when ENFLONSIA was given concomitantly with routine childhood vaccines, the safety profile of the co-administered regimen was generally comparable to the safety profile when ENFLONSIA and childhood vaccines were administered alone.
- Immunogenicity
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies. In Trial 004 and Trial 007, after receiving the approved recommended dose in RSV season 1, 6% (120/2112) and 5% (13/291) of participants were ADA-positive on Day 150, respectively; and 12% (124/1033) and 13% (34/261) of participants were ADA-positive through Day 240, respectively. The impact of ADA on efficacy is unknown due to the low rates of MALRI and ADA. There was no identified impact of ADA on pharmacokinetics, RSV serum neutralizing activity or safety of ENFLONSIA during RSV season 1.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis, mutagenesis and reproductive toxicity studies have not been performed with ENFLONSIA.
Clinical Studies
Description of Clinical Trials
Trial 004 (NCT04767373). Study Population: Infants born at ≥29 weeks GA from birth up to 1 year entering their first RSV season. Trial 007 (NCT04938830). Study Population:Infants born at ≤35 weeks GA, or infants with CLD of prematurity or hemodynamically significant CHD from birth up to 1 year entering their first RSV season.
Prevention of RSV-Associated Disease in Neonates and Infants (≥29 Weeks GA) Entering Their First RSV Season (Trial 004)
- Trial 004 was a Phase 2b/3, randomized, double-blind placebo-controlled, multi-site trial conducted in 22 countries from the Northern and Southern Hemispheres to evaluate the efficacy of ENFLONSIA in early and moderate preterm infants (≥29 to <35 weeks GA) and late preterm and full-term infants (≥35 weeks GA).
- The trial assessed the efficacy of ENFLONSIA in the prevention of RSV-associated disease across a spectrum of severity. Participants were randomized 2:1 to receive a single 105 mg dose of ENFLONSIA or saline placebo by IM injection.
- Among participants who received ENFLONSIA or saline placebo, the median age of infants was 3.1 months (range: 0 to 12 months); 80% were less than 6 months; 16% were greater than or equal to 6 to less than 9 months, 4% were greater than or equal to 9 months of age, and 51% were male. Of these participants, 18% were GA greater than or equal to 29 weeks and less than 35 weeks, and 82% were GA greater than or equal to 35 weeks.
- The racial distribution was as follows: 45% were White; 27% were Asian; 14% were Black or African American; 12% were Multi-racial and 2% were American Indian or Alaska Native; 28% were of Hispanic or Latino ethnicity.
- The primary endpoint was the incidence of RSV-associated Medically Attended Lower Respiratory Infection (MALRI) characterized as cough or difficulty breathing and requiring ≥1 indicator of LRI (wheezing, rales/crackles) or severity (chest wall in-drawing/retractions, hypoxemia, tachypnea, dehydration due to respiratory symptoms) through 150 days after dosing.
- Medically Attended (MA) includes all healthcare provider visits in settings such as outpatient clinic, clinical study site, emergency department, urgent care center, and/or hospital.
- The statistical criterion for success required the lower bound of the 95% CI of efficacy to be greater than 25%.
- RSV-associated hospitalization through 150 days after dosing was evaluated as a key secondary endpoint. The statistical criterion for success required the lower bound of the 95% CI of efficacy to be greater than 0%. Both efficacy endpoints required an RSV-positive RT-PCR nasopharyngeal (NP) sample.
Prevention of RSV-Associated Disease in Infants Born at ≤35 Weeks Gestational Age and Infants with CLD of Prematurity or Hemodynamically Significant CHD Entering Their First RSV Season (Trial 007)
- Trial 007 is a Phase 3, randomized, partially-blind, palivizumab-controlled, multi-site trial conducted in 27 countries from the Northern and Southern Hemispheres to evaluate the efficacy of ENFLONSIA in early (<29 weeks GA) or moderate preterm infants (≥29 to ≤35 weeks GA), and infants with chronic lung disease of prematurity or congenital heart disease of any GA, who are at increased risk for severe RSV disease.
- Participants were randomized to receive ENFLONSIA or palivizumab by IM injection. Participants randomized to ENFLONSIA received a single 105 mg dose on Day 1 followed by a dose of placebo one month later; 15 mg/kg palivizumab was administered on Day 1 and every month thereafter for a total of 3 to 5 doses.
- Among participants who received ENFLONSIA or palivizumab, the median age of infants was 2.5 months (range: 0 to 12 months); 89% were less than 6 months; 9% were greater than or equal to 6 to less than 9 months, 2% were greater than or equal to 9 months of age; and 50% were male.
- Of these participants, 28% had CLD, 11% had CHD, 6% were GA less than 29 weeks with neither CLD nor CHD and 55% were GA greater than or equal to 29 weeks with neither CLD nor CHD. The racial distribution was as follows: 52% were White; 18% were Asian; 15% were Black or African American; 12% were Multi-racial, and 1% were American Indian or Alaska Native; 32% were of Hispanic or Latino ethnicity.
- The efficacy of ENFLONSIA in infants at increased risk for severe RSV disease, including preterm infants and infants with chronic lung disease of prematurity or congenital heart disease was established by extrapolation of efficacy of ENFLONSIA from Trial 004 to Trial 007 based on similar pharmacokinetic exposure. * The incidence rate of RSV-associated MALRI (requiring ≥1 indicator of LRI or severity) through 150 days after dosing was generally comparable between ENFLONSIA (incidence rate=3.6%, 95% CI: 2.0, 6.0) and palivizumab (incidence rate=2.9%, 95% CI: 1.5, 5.2). The incidence rate of RSV-associated hospitalization through 150 days after dosing was generally comparable between ENFLONSIA (incidence rate=1.3%, 95% CI: 0.4, 2.9) and palivizumab (incidence rate=1.5%, 95% CI: 0.5, 3.2).
How Supplied
- ENFLONSIA injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution supplied as follows:
Carton containing one or ten single-dose prefilled type I glass syringe(s) with Luer Lock and plunger stopper. The prefilled syringe is not made with natural rubber latex.
Add supply table
Storage
- Store prefilled syringes under refrigeration at 36°F to 46°F (2°C to 8°C).
- Keep the prefilled syringe in the original carton to protect from light until time of use.
- ENFLONSIA may be kept at room temperature between 68°F to 77°F (20°C to 25°C) for a maximum of 48 hours. After removal from the refrigerator, ENFLONSIA must be used within 48 hours or discarded.
- Do not freeze. Do not shake.
Images
Drug Images
{{#ask: Page Name::Clesrovimab-cfor |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
Add Display panel {{#ask: Label Page::Clesrovimab-cfor |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- Advise the child’s caregiver to read the FDA-approved patient labeling (Patient Information).
- Hypersensitivity Reactions Including Anaphylaxis
Inform the patient’s caregiver of the signs and symptoms of potential hypersensitivity reactions, and advise the caregiver to seek medical attention immediately if the infant experiences a hypersensitivity reaction to ENFLONSIA.
- Dosage and Administration
Advise the caregiver that the infant will receive ENFLONSIA by IM injection by a healthcare provider
Precautions with Alcohol
Alcohol-Clesrovimab-cfor interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
ENFLONSIA™ (en-flahn-see-ah)
Look-Alike Drug Names
There is limited information regarding Clesrovimab-cfor Look-Alike Drug Names in the drug label.
Price
References
The contents of this FDA label are provided by the National Library of Medicine.